Publications for Mitchell S. Cairo mitchell_cairo@nymc.edu

NYMC School of Medicine
NYMC School of Health Sciences and Practice
  • Abikoff, C. A., Nash, M., Nickerson, B., Harrison, L., Shi, Q., Zhang, X., . . . Cairo, M. S. (2016). A pilot study of unrelated cord blood (UCB) transplantation followed by unmatched human placental derived stem cells (HPDSC) in children and young adults with malignant and non-malignant diseases. Pediatric Blood & Cancer, 63(Suppl S1), S96. doi:10.1002/pbc.25998

  • Awasthi, A., Ayello, J., van de Ven, C., Chakraborty, S., Barth, M., & Cairo, M. (2016). Polatuzumab vedotin (PV, ANTI-CD79B-VC-MMAE) significantly increased apoptosis/reduced cell proliferation and improved survival against Burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBL). Pediatric Blood & Cancer, 63(Suppl 3), S208. This material can be found here.

  • Awasthi, A., Ayello, J., van de Ven, C., Love, A. C., & Cairo, M. S. (2016). Polatuzumab vedotin; antibody drug conjugates (ADC, anti-CD79b-vc-MMAE, PV) significantly enhances in-vitro cell death against CD79b+ Burkitt lymphoma (BL) /primary mediastinal large B cell lymphoma (PMBL) and improved overall survival against rituximab sensitive/resistant-BL NSG xenograft mice. Blood, 128(22), 4126. This material can be found here.

  • Ayello, J., Chu, Y., Keever-Taylor, C. A., Talano, J. A., Weinberg, R., Abikoff, C. M.,. . . Cairo, M. S. (2016). A pilot trial of unmatched human placenta-derived stem cells (HPDSCs) in conjunction with unrelated cord blood transplantation (UCBT) in children and young adults with malignant and non-malignant disease (IND 14949). Blood, 128(22), 4671.

  • Ayello, J., Chu, Y., Keever-Taylor, C. A., Talano, J. A., Weinberg, R., Abikoff, C. M., . . . Cairo, M. S. (2016). Familial haploidentical (FHI) allogeneic stem cell transplantation utilizing CD34 enrichment and T cell addback in children, adolescents & adults with high-risk sickle cell disease. Rapid engraftment, low incidence of AGVHD, and sustained donor chimerism. Blood, 128(22), 1245. 

  • Ayello, J., Keever-Taylor, C., Weinberg, R., Grossman, B. J., Shenoy, S., Talano, J. X., . . . Cairo, M. (2016). Processing of G-CSF mobilized peripheral blood stem cells (PBSC) from parental haploidentical sickle cell trait donors undergoing CD34 enrichment with T cell addback in children, adolescents and adults with high risk sickle cell disease (IND 14359). Transfusion, 56(S4), 5A.

  • Barth, M., Goldman, S., Oesterheld, J., Heym, K., Harrison, L., Nickerson, B., & Cairo, M. (2016). Preliminary results of the Reduced Burden of Oncologic Therapy (Reboot) trial in children, adolescents and young adults with intermediate and high risk aggressive B-cell non Hodgkin lymphoma. Pediatric Blood & Cancer, 63(Suppl S1), S16.

  • Cairo, M. S., Talano, J. M., Moore, T. B., Weinberg, R., Keever-Taylor, C. A., Braniecki, S., . . . Abikoff, C., (2016). Familial haploidentical (FHI) allogeneic stem cell transplantation utilizing CD34 enrichment and T cell addback in children, adolescents & adults with high-risk sickle cell disease. rapid engraftment, low incidence of AGVHD, and sustained donor chimerism. Biology of Blood and Marrow Transplantation, 22(3), S367-S368.

  • Chu, Y., Brand, P., Morris, E., Lee, F., Talano, J. M., Shenoy, S., . . . Cairo, M. S. (2016). Natural killer cell reconstitution following familial haploidentical (FHI) CD34 enriched stem cell transplantation with T-cell add back in patients with high risk sickle cell disease (SCD) (IND 14359). Biology of Blood and Marrow Transplantation, 22(3), S151-S152. doi:10.1016/j.bbmt.2015.11.502

  • Chu, Y., Lee, F., Ayello, J., Hang, B., Zhang, M., Wong, H., . . . Cairo, M. (2016). Therapeutic effects of Alt-803, an IL-15 superagonist, in combination with anti-CD20 chimeric antigen receptor modified expanded natural killer cells against Burkitt lymphoma (BL). Cytotherapy, 18(6), S59. doi:10.1016/j.jcyt.2016.03.194

  • Chu, Y., Lee, F., Ayello, J., Hang, B., Zhang, M., Wong, H., . . . Cairo, M. S. (2016). Therapeutic effects of Alt-803, an IL-15 superagonist, in combination with anti-CD20 chimeric antigen receptor modified expanded natural killer cells against Burkitt lymphoma (BL). Biology of Blood and Marrow Transplantation, 22(3), S151. doi:10.1016/j.bbmt.2015.11.501

  • Chu, Y., Lee, F., Hamby, C., Misarti, J., Hang, B., Ayello, J., . . . Cairo, M. (2016). Regulation of cytokine release and anti-tumor effect of anti-CD20 CAR modified expanded natural killer cells by Alt-803, an IL-15 superagonist. Experimental Hematology, 44(9), S64. doi:10.1016/j.exphem.2016.06.107

  • Chu, Y., Yahr, A., Cheng, B., Hang, B., Ayello, J., Barth, M., & Cairo, M. S. (2016). Enhanced in-vitro and in-vivo targeting of rituximab sensitive and resistant Burkitt lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer cells in combination with a histone deacetylase inhibitor, romidepsin. Biology of Blood and Marrow Transplantation, 22(3), S392. doi:10.1016/j.bbmt.2015.11.915

  • Chu, Y., Yahr, A., Cheng, B., Hang, B., Ayello, J., Barth, M., & Cairo, M. S. (2016). Enhanced in-vitro and in-vivo targeting of rituximab sensitive and resistant Burkitt lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer cells in combination with a histone deacetylase inhibitor, romidepsin. Pediatric Blood & Cancer, 63(Suppl S1), S96.

  • Flower, A., Chu, Y., Ayello, J., Kurtzberg, J., Lee, D., & Cairo, M. S. (2016). Ex-vivo expansion of previously cryopreserved, thawed and re-cryopreserved cord blood mononuclear cells (CBMC) utilizing K562-mbIL21-41BBL; potential for adoptive cellular immunotherapy post umbilical cord blood transplantation (UCBT). Biology of Blood and Marrow Transplantation, 22(3), S153. doi:10.1016/j.bbmt.2015.11.504

  • Ghersin, Z., Harrison, L., Abrams, D.,  Fabricatore, S., Militano, O., Van de Ven, C., . . . Cairo, M. S. (2016). Low molecular weight heparin (LMWH) prophylaxis to prevent sinusoidal obstructive syndrome (SOS) in pediatric hematopoietic stem cell transplant (HSCT) recipients. Biology of Blood and Marrow Transplantation, 22(3), S289-S290. doi:10.1016/j.bbmt.2015.11.743

  • Hamill, D., Baxter-Lowe, L. A., Shenoy, S., Moore, T. B., Morris, E., Abikoff, C., . . . Cairo, M. S. (2016). Robust donor chimerism and engraftment following familial haploidentical (FHI) (CD34 enriched and T-cell addback) allogeneic stem cell transplantation in patients with high risk sickle cell disease (SCD). Biology of Blood and Marrow Transplantation, 22(3), S95-S96. doi:10.1016/j.bbmt.2015.11.396

  • Hochberg, J., Harrison, L., Morris, E., Militano, O., Brand, P., Fabricatore, S., . . . Cairo, M. S. (2016). Safety of liposomal cytarabine CNS prophylaxis in children, adolescent and young adult hematopoietic stem cell transplant recipients with acute leukemia and non-hodgkin lymphoma. Bone Marrow Transplantation, 51(9), 1249-1252.  doi:10.1038/bmt.2016.100

  • Hochberg, J., Oesterheld, J., Militano, O., Klejmont, L., Harrison, L., Nickerson, B., & Cairo, M. (2016). Final phase I results of mitoxantrone in combination with clofarabine in children with refractory/relapsed acute leukemia. Pediatric Blood & Cancer, 63(Suppl S1), S7. doi:10.1002/pbc.25998

  • Hochberg, J., Oesterheld, J., Militano, O., Klejmont, L., Harrison, L., Nickerson, B., & Cairo, M. (2016). Phase I results of mitoxantrone in combination with clofarabine in children, adolescents and young adults with refractory/relapsed acute leukemia. Pediatric Blood & Cancer, 63(Suppl 3), S108. doi:10.1158/1538-7445.AM2016-3203

  • Hochberg, J., Oesterheld, J., Militano, O., Klejmont, L., Harrison, L., Nickerson, B., & Cairo, M. S. (2016). Phase I results of mitoxantrone in combination with clofarabine in children with refractory/relapsed acute leukemia. Cancer Research, 76(14 (Suppl)), 3203. doi:10.1158/1538-7445.AM2016-3203

  • Keever-Taylor, C. A., Weinberg, R., Grossman, B., Shenoy, S., Talano, J. A., Moore, T. B., . . . Cairo, M. S. (2016). Collection and processing outcomes of G-CSF mobilized peripheral blood stem cells (PBSC) collected from parental haploidentical stem cell sickle cell trait donors of patients undergoing CD34 enriched transplantation for higher risk sickle cell disease (IND). Biology of Blood and Marrow Transplantation, 22(3 (Suppl 1)), S383-S384. doi:10.1016/j.bbmt.2015.11.899

  • Lee, S., Yin, C., Shah, T., Ayello, J., Morris, E., van de Ven, C., & Cairo, M. (2016). Ruxolitinib, A JAK1/JAK2 inhibitor, significantly prolongs survival in both primary mediastinal B-cell lymphoma & hodgkin lymphoma xenograft NSG mouse model: A potential targeted adjuvant therapy. Pediatric Blood & Cancer, 63(Suppl 3), S10.

  • Lee, S., Yin, C., Shah, T., Ayello, J., Morris, E., Van De Ven, C., & Cairo, M. S. (2016). Upregulation of DLEU1 significantly prolongs survival in a rituximab-treated DLEU1 knockout human Burkitt lymphoma (BL) xenograft NSG mouse model: DLEU1 may act as a tumor suppressor gene in pediatric BL. Cancer Research, 76(14 (Suppl)), 3838. doi:10.1158/1538-7445.AM2016-3838

  • Liao, Y., Ivanova, L., Plumer, T., Morris, E., Gurney, J., Herb, S., . . . Cairo, M. (2016). Potential use of human placental derived stem cells (HPDSCs) as a novel stem cell source for the treatment of recessive dystrophic epidermolysis bullosa (RDSB). Cytotherapy, 18(6), S12. doi:10.1016/j.jcyt.2016.03.031

First Prev 1 2 3 4 5 Next Last